Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Summary

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

Timeline

Start

2021-02-16

Primary completion

2024-10-17

Completion

2024-10-17

Publications

• Rahim AA, Kurian MA, Zhou H, Ferguson R, Tabrizi SJ, Lignani G, Aquilina K, Waddington SN. Genetic therapies for neurological diseases. Pharmacol Rev. 2026 Jan;78(1):100093. doi: 10.1016/j.pharmr.2025.100093. Epub 2025 Oct 3.

Drugs

Indications